- Trials with a EudraCT protocol (1,131)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,131 result(s) found for: Secondary growth.
Displaying page 1 of 57.
EudraCT Number: 2019-000844-81 | Sponsor Protocol Number: MS306 | Start Date*: 2019-05-31 |
Sponsor Name:Ipsen Pharma | ||
Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF CHILDREN AND ADOLESCENTS WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: AN OPEN-LABEL, MULTI-CENTER, EXTENSION S... | ||
Medical condition: Children and adolescents with growth failure associated with primary insulin-like growth factor deficiency (IGFD). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-002892-16 | Sponsor Protocol Number: NN8640-4054 | Start Date*: 2014-10-07 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-00... | |||||||||||||
Medical condition: Growth hormone deficiency in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DE (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002736-13 | Sponsor Protocol Number: TV1106-IMM-30022 | Start Date*: 2015-08-19 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd. | |||||||||||||
Full Title: A phase 3, multicenter, randomized, open-label, comparator-controlled study to assess safety and tolerability of weekly TV-1106 compared to daily rhGH (Genotropin®) in adults with growth hormone-de... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Completed) SE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) ES (Prematurely Ended) SI (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) HR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002507-32 | Sponsor Protocol Number: IBD8 | Start Date*: 2004-10-11 |
Sponsor Name:Royal Hospital For Sick Children, Yorkhill Division | ||
Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with Inflammatory bowel disease (IBD) and growth failure. | ||
Medical condition: Growth retardation secondary to inflammatory bowel disease in children | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004153-25 | Sponsor Protocol Number: JIA6 | Start Date*: 2004-12-10 |
Sponsor Name:Royal Hospital For Sick Children, Yorkhill Division | ||
Full Title: Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with juvenile idiopathic arthritis (JIA) and growth failure. | ||
Medical condition: Growth retardation secondary to juvenile idiopathic arthritis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-001020-36 | Sponsor Protocol Number: MS301 | Start Date*: 2019-05-31 |
Sponsor Name:Ipsen Pharma | ||
Full Title: RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATI... | ||
Medical condition: Children with growth failure associated with primary insulin-like growth factor deficiency (IGFD). | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-004316-73 | Sponsor Protocol Number: 3189 | Start Date*: 2006-08-23 |
Sponsor Name:Royal Liverpool University hospital | ||
Full Title: The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A ... | ||
Medical condition: Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001681-25 | Sponsor Protocol Number: 23681 | Start Date*: 2015-07-15 |
Sponsor Name:Merck KGaA | ||
Full Title: An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Ex... | ||
Medical condition: Small for Gestational Age | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-004580-39 | Sponsor Protocol Number: TOSCA_GHDDP | Start Date*: 2018-07-18 | |||||||||||
Sponsor Name:AOU FEDERICO II | |||||||||||||
Full Title: Treatment of Growth Hormone Deficiency associated with Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Study | |||||||||||||
Medical condition: Growth Hormone Deficiency associated with Chronic Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000384-26 | Sponsor Protocol Number: BPLG-005 | Start Date*: 2005-11-10 | |||||||||||
Sponsor Name:LG Life Science Ltd. [...] | |||||||||||||
Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency. | |||||||||||||
Medical condition: growth hormone deficiency in adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003586-41 | Sponsor Protocol Number: A6281289 | Start Date*: 2007-12-17 | |||||||||||
Sponsor Name:Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | |||||||||||||
Full Title: Placebo-controlled trial on the efficacy of growth hormone replacement therapy in patients with growth hormone deficiency after traumatic brain injury | |||||||||||||
Medical condition: Growth hormone deficiency after traumatic brain injury | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002802-34 | Sponsor Protocol Number: Sandoz/OMNI/F/01/03 | Start Date*: 2015-07-03 |
Sponsor Name:Sandoz SAS | ||
Full Title: Multicentre study to evaluate the efficacy and safety of a liquid formulation of recombinant growth hormone, Omnitrope® 3.3mg/mL, in the treatment of pre-pubertal children of small stature sufferin... | ||
Medical condition: Small stature secondary to growth hormone insufficiency deficiency | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-001826-61 | Sponsor Protocol Number: 11‐HM10560A‐201 | Start Date*: 2011-07-29 | |||||||||||
Sponsor Name:Hanmi Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: A phase II, randomized, active controlled, open label study of safety and efficacy of HM10560A a Long-acting rhGH-HMC001 conjugate in treatment of subjects suffering from adult growth hormone defic... | |||||||||||||
Medical condition: Adult growth hormone deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004468-69 | Sponsor Protocol Number: TV1106-IMM-20001 | Start Date*: 2014-06-11 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries, Ltd. | |||||||||||||
Full Title: A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone (Genotropin®) Therapy in Treatment-Naive,... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) RO (Ongoing) GR (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000356-17 | Sponsor Protocol Number: 2 79 58035 700 | Start Date*: Information not available in EudraCT |
Sponsor Name:Beaufour Ipsen Pharma | ||
Full Title: PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ USING A NOVEL CAPILLARY BLOOD COLLECTION METHOD | ||
Medical condition: growth failure associated with: - inadequate growth hormone secretion - Turner syndrome, confirmed by karyotype - chronic renal insufficiency up to renal transplantation | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) IT (Completed) DK (Completed) AT (Completed) SE (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004975-37 | Sponsor Protocol Number: TV1106-GHD-201 | Start Date*: 2013-01-21 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd. | |||||||||||||
Full Title: A 64-Week (12-week core phase and 52-week safety extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults with G... | |||||||||||||
Medical condition: Growth hormone deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) GR (Completed) SI (Completed) DE (Completed) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021523-28 | Sponsor Protocol Number: ACP-001 CT-002 | Start Date*: 2010-09-02 | |||||||||||
Sponsor Name:Ascendis Pharma A/S | |||||||||||||
Full Title: A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients with Growth Hormone Deficiency ... | |||||||||||||
Medical condition: Growth Hormone Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DK (Completed) SE (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002698-13 | Sponsor Protocol Number: GX-H9-002 | Start Date*: 2015-01-14 | |||||||||||
Sponsor Name:Genexine, Inc | |||||||||||||
Full Title: A randomized, active-controlled, multiple-dose, open-label study to evaluate the safety, tolerability, and efficacy of the long-acting antibody-fused recombinant human growth hormone (GX-H9) in adu... | |||||||||||||
Medical condition: Adult Growth Hormone Deficiency (AGHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) SE (Completed) DE (Completed) GR (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015739-34 | Sponsor Protocol Number: FRA.GHAT.2009 | Start Date*: 2009-12-09 |
Sponsor Name:Goethe-Universität Frankfurt/Main | ||
Full Title: Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) | ||
Medical condition: This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children wi... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003678-82 | Sponsor Protocol Number: CHDR0606 | Start Date*: 2007-07-10 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: Pharmacokinetics and effects of oral clonidine in children with suspected Growth Hormone deficiency | |||||||||||||
Medical condition: Clonidine is studied in the paediatric population, more specific children with short stature. It is used as a diagnostic tool to establish Growth Hormone reserve in routine practice. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
